title: Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
abstract: The purposes of this study were to evaluate the antitumor activity of S-1 (1 M tegafur, 0.4 M 5-chloro-2,4-dihydroxypyridine and 1 M potassium oxonate) on human lung tumor xenografts, as compared with other fluoro-pyrimidines, and to investigate the relationships between fluoropyrimidine antitumor activities and four distinct enzymatic activities involved in the phosphorylation and degradation pathways of 5-fluorouracil (5-FU) metabolism. S-1, UFT (1 M tegafur-4 M uracil), 5'-deoxy-5-fluorouridine (5'-DFUR), capecitabine and 5-FU were administered for 14 consecutive days to nude mice bearing lung tumor xenografts. S-1 showed stronger tumor growth inhibition in four of the seven tumors than the other drugs. Cluster analysis, on the basis of antitumor activity, indicated that S-1/UFT and 5'-DFUR/capecitabine/5-FU could be classified into another group. We investigated tumor thymidylate synthase content, dihydropyrimidine dehydrogenase (DPD) activity, thymidine phosphorylase (TP) activity and orotate phosphoribosyl transferase activity in seven human lung tumor xenografts and performed regression analyses for the antitumor activities of fluoropyrimidines. There were inverse correlations between antitumor and DPD activities for 5'-DFUR (r=-0.79, P=0.034), capecitabine (r=-0.56, P=0.19) and 5-FU (r=-0.86, P=0.013). However, no such correlations were observed for S-1 and UFT. These findings suggest that S-1 containing a potent DPD inhibitor may have an antitumor effect on lung tumors, with high basal DPD activity, superior to those of other fluoropyrimidines.
authors.affiliation: Cancer Research Laboratory, Product Lifecycle Management Department, Taiho Pharmaceutical Co., Ltd., 1-27 Kanda-Nishikicho, Chiyoda-ku, Tokyo 101-8444, Japan. ttakechi@taiho.co.jp
authors.forename: Teiji
authors.initials: T
authors.lastname: Takechi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Okabe
authors.forename: Kazumasa
authors.initials: K
authors.lastname: Ikeda
authors.forename: Akio
authors.initials: A
authors.lastname: Fujioka
authors.forename: Fumio
authors.initials: F
authors.lastname: Nakagawa
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ohshimo
authors.forename: Kenji
authors.initials: K
authors.lastname: Kitazato
authors.forename: Masakazu
authors.initials: M
authors.lastname: Fukushima
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D045744:Cell Line, Tumor; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism*; D005467:Floxuridine / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009962:Orotate Phosphoribosyltransferase / Q000378:metabolism; D010094:Oxonic Acid / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013939:Thymidine Phosphorylase / Q000378:metabolism; D016896:Treatment Outcome; D014498:Uracil / Q000008:administration & dosage; D023041:Xenograft Model Antitumor Assays / Q000379:methods*
chemical_list: D000970:Antineoplastic Agents; D011725:Pyridines; D005467:Floxuridine; D003841:Deoxycytidine; D005641:Tegafur; C489337:potassium oxonate; D014498:Uracil; D010094:Oxonic Acid; D000069287:Capecitabine; D042943:Dihydrouracil Dehydrogenase (NADP); D009962:Orotate Phosphoribosyltransferase; D013939:Thymidine Phosphorylase; D005472:Fluorouracil; C104201:gimeracil; C025034:doxifluridine